Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Clive Roberts who wrote (21)	10/20/1996 9:54:00 PM
From: John Metcalf	of 1494

All three products are in clinical trials. News could come from any direction. Memantine: Beginning a Phase II trial against AIDS dementia sponsored by the AIDS Clinical Trials Group of the National Institutes of Health. Phase I results against neuropathic pain due in February. Has begun a Phase I study for neuroprotection in stroke, traumatic brain injury, neuropathic pain, and neurodegenerative conditions (like Alzheimers). Dynorphin A -- successful Phase II results in reducing morphine use in post-surgical pain. A partner is being sought. Corticotropin-releasing factor: Two Phase I/II studies were done. A phase II against arthritis is beginning. Either further clinical results, new products, or a partnership arrangement could lift stock price at any time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next